Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
FRC
First Republic Bank
FRC
|
+$734M |
| 2 |
Boeing
BA
|
+$493M |
| 3 |
Pfizer
PFE
|
+$478M |
| 4 |
UnitedHealth
UNH
|
+$440M |
| 5 |
Honeywell
HON
|
+$364M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$1.05B |
| 2 |
Advanced Micro Devices
AMD
|
+$447M |
| 3 |
TSMC
TSM
|
+$441M |
| 4 |
Alphabet (Google) Class A
GOOGL
|
+$372M |
| 5 |
ExxonMobil
XOM
|
+$321M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.34% |
| 2 | Technology | 16.84% |
| 3 | Consumer Discretionary | 12.66% |
| 4 | Industrials | 10.11% |
| 5 | Consumer Staples | 9.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SIEN
3701
DELISTED
Sientra, Inc.
SIEN
| $42K | ﹤0.01% |
27,570
-69,040
| -71% | -$123K |
|
|
SQZ
3702
DELISTED
SQZ Biotechnologies Company
SQZ
| $42K | ﹤0.01% |
74,303
-39,725
| -35% | -$29.3K |
|
|
IH
3703
iHuman
IH
$67.5M
| $41K | ﹤0.01% |
12,700
+200
| +2% | +$644 |
|
|
RTB
3704
RTB Digital
RTB
$236M
| $41K | ﹤0.01% |
284
+25
| +10% | +$4.53K |
|
3705
Sonoma Pharmaceuticals
SNOA
$6.41M
| $41K | ﹤0.01% |
2,098
-1,625
| -44% | -$41.9K |
|
|
NBRV
3706
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
| $41K | ﹤0.01% |
23,361
+300
| +1% | +$504 |
|
3707
Xenetic Biosciences
XBIO
$7.54M
| $40K | ﹤0.01% |
9,951
-4,389
| -31% | -$21.3K |
|
|
EBET
3708
DELISTED
EBET, INC. Common Stock
EBET
| $40K | ﹤0.01% |
3,230
+1,710
| +113% | +$28.7K |
|
|
PRDS
3709
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
| $40K | ﹤0.01% |
30,500
+614
| +2% | +$1K |
|
|
ITRM
3710
DELISTED
Iterum Therapeutics
ITRM
| $39K | ﹤0.01% |
38,884
+1,800
| +5% | +$2.08K |
|
|
BIOL
3711
DELISTED
Biolase, Inc.
BIOL
| $39K | ﹤0.01% |
1,388
+957
| +222% | +$46.6K |
|
|
AGIL
3712
DELISTED
AgileThought Inc
AGIL
| $39K | ﹤0.01% |
+12,300
| New | +$50.3K |
|
3713
Cyclerion Therapeutics
CYCN
$18.3M
| $38K | ﹤0.01% |
4,335
-4,844
| -53% | -$61.1K |
|
3714
GT Biopharma
GTBP
$10.7M
| $38K | ﹤0.01% |
2,313
+773
| +50% | +$17.7K |
|
|
BNKK
3715
Bonk Inc
BNKK
$8.16M
| $38K | ﹤0.01% |
2,426
+626
| +35% | +$12.6K |
|
|
DCOY
3716
Decoy Therapeutics
DCOY
$1.88M
| $38K | ﹤0.01% |
14
+3
| +27% | +$9.65K |
|
|
RBT
3717
DELISTED
Rubicon Technologies, Inc.
RBT
| $38K | ﹤0.01% |
+7,213
| New | +$74.6K |
|
|
INFI
3718
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| $38K | ﹤0.01% |
235,000
-184,600
| -44% | -$82K |
|
|
PTE
3719
DELISTED
PolarityTE, Inc. Common Stock
PTE
| $38K | ﹤0.01% |
75,622
+1,700
| +2% | +$1.24K |
|
3720
IGC Pharma
IGC
$30.7M
| $37K | ﹤0.01% |
110,300
-111,711
| -50% | -$41.9K |
|
3721
Kaixin Holdings
KXIN
$8.47M
| – | – |
0
| – | – |
|
3722
Lexaria Bioscience
LEXX
$13.4M
| $37K | ﹤0.01% |
907
+140
| +18% | +$5.98K |
|
3723
Momentus
MNTS
$92.5M
| $37K | ﹤0.01% |
5
+3
| +150% | +$30.4K |
|
3724
Rezolute
RZLT
$443M
| $37K | ﹤0.01% |
19,400
+1,800
| +10% | +$4.05K |
|
3725
WidePoint Corp
WYY
$115M
| $37K | ﹤0.01% |
20,500
+3,600
| +21% | +$7.23K |
|
Similar funds
Jim Simons's Q1 2023 Portfolio in Review
As of Q1 2023, Jim Simons held 4,600 positions worth $75.4B, up 3.1% from $73.1B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Jim Simons's Q1 2023 filing shows 524 new, 1,665 increased, 1,689 reduced and 668 closed positions. Its largest new stake was Honeywell: 1,937,917 shares worth $349M. The largest sale was Apple, an estimated $1.05B.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, down from 21% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q1 2023 buy was Honeywell: 1,937,917 shares worth $349M.
- Jim Simons added most to First Republic Bank in Q1 2023, an estimated $734M increase.
- Jim Simons's biggest Q1 2023 reduction was Apple, cutting an estimated $1.05B.
- Jim Simons fully exited Advanced Micro Devices in Q1 2023, selling an estimated $447M.
- Jim Simons's ten largest holdings make up 11% of its $75.4B portfolio in Q1 2023.
- Jim Simons opened 524 new positions and closed 668 in Q1 2023.
- Jim Simons's portfolio value rose 3.1% quarter-over-quarter to $75.4B.
Based on Renaissance Technologies's 13F filing for Q1 2023, filed 12 May 2023.